Trial Profile
A Phase 2, Open Label, Randomized Trial Evaluating Ixazomib Compared to Ixazomib-Lenalidomide Combination Maintenance Therapy for Frontline Multiple Myeloma Patients
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Oct 2023
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Biomira USA
- 23 Oct 2023 Status changed from recruiting to discontinued.
- 16 Sep 2019 Status changed from not yet recruiting to recruiting.
- 17 Nov 2018 New trial record